Myriad Genetics (MYGN) Cash from Financing Activities (2009 - 2026)

Myriad Genetics has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$3.0 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 122.06% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at $47.6 million (up 217.33% YoY), while the FY2025 annual figure was $64.2 million, up 967.57% from the prior year.
• Cash from Financing Activities advanced to -$3.0 million in Q1 2026, from -$8.2 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for MYGN reached as high as $121.9 million in Q4 2023 and fell as low as -$8.8 million in Q1 2024.
• The 5-year median for Cash from Financing Activities is -$2.1 million (2022), against an average of $11.7 million.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 5904.76% — and 2025, when it tumbled 490.48%.
• A 5-year view of Cash from Financing Activities shows it stood at -$2.1 million in 2022, then surged by 5904.76% to $121.9 million in 2023, then plunged by 98.28% to $2.1 million in 2024, then plunged by 490.48% to -$8.2 million in 2025, then jumped by 63.41% to -$3.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$3.0 million, -$8.2 million, and $56.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.